Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.
Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.